Premium
Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid‐1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics
Author(s) -
Schwartz Jules I.,
Dunbar Stephanie,
Yuan Jinyu,
Li Susie,
Miller Deborah L.,
Rosko Kim,
JohnsonLevonas Amy O.,
Lasseter Kenneth C.,
Wagner John A.
Publication year - 2009
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270008325930
Subject(s) - inverse agonist , pharmacokinetics , pharmacology , agonist , cannabinoid , cannabinoid receptor , chemistry , active metabolite , medicine , endocrinology , receptor
Taranabant, an orally active, potent, and highly selective CB‐1 receptor inverse agonist, is being developed for the treatment of obesity. This randomized, placebo‐controlled, multiple‐dose, crossover study evaluated the effect of taranabant on the pharmacokinetics of ethinyl estradiol and norelgestromin in healthy women receiving ≥3 months of therapy with oral contraceptives. Nineteen participants with normal menstrual cycles received oral contraceptives on days 1 to 21 during 2 consecutive contraceptive cycles. Participants received taranabant 6 mg/day or placebo on days 1 to 21 of each contraceptive cycle. Plasma samples were collected predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours postdose on day 21 of each cycle for determination of AUC 0–24 h and C max of ethinyl estradiol and norelgestromin. Lack of a clinically important effect was declared if the 90% confidence intervals for the geometric mean ratio of AUC 0–24 h and C max in the absence and presence of taranabant were contained within the predefined bounds of (0.8, 1.25). The geometric mean ratios and 90% confidence intervals of ethinyl estradiol and norelgestromin, respectively, were 0.93 (0.87, 1.00) and 1.02 (0.96, 1.09) for AUC 0–24 h and 0.95 (0.88, 1.01) and 0.95 (0.88, 1.01) for C max . In summary, coadministration of multiple‐dose taranabant 6 mg with oral contraceptives did not lead to clinically meaningful alterations in the pharmacokinetic profiles of ethinyl estradiol or norelgestromin.